MLST8

Across TCGA pan-cancer cohorts, MLST8 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MLST8 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MLST8 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MLST8 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

CCRCC, COAD, and LSCC are the cancer types where MLST8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.626	1.000	.003	29	view →
COAD	DFS	Tertile	II,III,IV	0.910	1.000	.030	12	view →
LSCC	DFS	Tertile	III,IV	0.684	1.000	.038	11	view →
LUAD	DFS	Median	II,III,IV	0.811	0.318	.013	10	view →
GBM	OS	Tertile	All	0.443	0.708	.039	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MLST8–CCRCC (OS)

Open the CCRCC breakdown →